Two Sigma Investments LP Reduces Position in Pfizer Inc. (NYSE:PFE)

Two Sigma Investments LP decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 38.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,302,731 shares of the biopharmaceutical company's stock after selling 3,299,112 shares during the period. Two Sigma Investments LP owned about 0.09% of Pfizer worth $140,681,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.0%

Shares of PFE stock opened at $22.83 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. The firm's 50 day moving average is $23.65 and its 200 day moving average is $25.32.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the business posted $0.82 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.